Table 1.
Features of the study population.
| Included patients n = 111 (%) | |
|---|---|
| Female Gender (%) | 76 (68.5) |
| Median age, years (range) | 41 (18–76) |
| Comorbidities: | 32 (28.8) |
| -Autoimmune disorders | 28 (85.7) |
| Persistent GIa symptomsb New onset GI symptoms |
33 (29.7) 13 (11.7) |
| Referred GI symptoms | |
| -Nausea/vomiting | 6 (5.4) |
| -Epigastric burning | 6 (5.4) |
| -Regurgitation | 8 (7.2) |
| -Dyspepsia | 6 (5.4) |
| -Dysphagia | 1 (0.9) |
| -Diarrhea | 9 (8.1) |
| -Constipation | 7 (6.3) |
| -Abdominal pain | 9 (8.1) |
| -Abdominal bloating | 19 (17.1) |
| GFDc compliance | |
| -Biagi score 0–2 | 5 (4.5) |
| -Biagi score 3–4 | 106 (95.5) |
| SARS-CoV2 diagnosis | 0 |
| Pneumonia diagnosis | 0 |
| Respiratory symptoms | |
| Total of patients | 19 (17.1) |
| -Fever (more than 3 days) | 10 (9) |
| -Cough (more than 1 week) | 6 (5.4) |
| -Asthenia/arthromyalgia | 10 (9) |
| -Anosmia/ageusia | 2 (1.8) |
| Quality of life items | |
| -definitely better | 1 (0.9) |
| -a little better | 6 (5.4) |
| -almost the same | 88 (79.3) |
| -a little worst | 15 (13.5) |
| -far worst | 1 (0.9) |
| SARS CoV-2 infection risk perceptiond | |
| -0 | 62 (55.9) |
| -1-4 | 16 (14.4) |
| -5-6 | 14 (12.6) |
| -7-10 | 19 (17.1) |
a
GI= Gastrointestinal
b
Already present at the last face-to-face visit
c
GFD= Gluten-free diet
d
Verbal rating scale from 0 (not at all) to 10 (very high)